Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs)

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1463-1473

  Sánchez Mora, Cristina ^a,b,c   Ramos Quiroga, Josep Antoni ^b,c,d   Garcia Martínez, Iris ^a,b   Fernàndez Castillo, Noelia ^e,f   Bosch, Rosa ^b,c   Richarte, Vanesa ^b   Palomar, Gloria ^b   Nogueira, Mariana ^b   Corrales, Montse ^b   Daigre, Constanza ^b   Martínez Luna, Nieves ^b   Grau Lopez, Lara ^b   Toma, Claudio ^e,f   Cormand, Bru ^e,f   Roncero, Carlos ^b,c,d   Casas, Miguel ^b,c,d   Ribasés, Marta ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

ADHD; Case control association study; HTR1B; MiRNA; SNP; SUD

Indexed keywords

MICRORNA; MICRORNA 182; MICRORNA 183; MICRORNA 96; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; EVALUATION; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE LOCATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HTR1B GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; RNA STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; SUBSTANCE ABUSE;

ADHD; CASE-CONTROL ASSOCIATION STUDY; HTR1B; MIRNA; SNP; SUD;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1B; SUBSTANCE-RELATED DISORDERS;

EID: 84886777256     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.07.002     Document Type: Article

References (106)

1. Abelson J.F., Kwan K.Y., O'Roak B.J., Baek D.Y., Stillman A.A., Morgan T.M., Mathews C.A., Pauls D.L., Rasin M.R., Gunel M., Davis N.R., Ercan-Sencicek A.G., Guez D.H., Spertus J.A., Leckman J.F., Dure L.S.t., Kurlan R., Singer H.S., Gilbert D.L., Farhi A., Louvi A., Lifton R.P., Sestan N., State M.W. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005, 310:317-320.
2. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
3. Arnsten A.F., Pliszka S.R. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol. Biochem. Behav. 2011, 99:211-216.
4. Baird A.L., Coogan A.N., Siddiqui A., Donev R.M., Thome J. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol. Psychiatry 2012, 17:988-995.
5. Banaschewski T., Becker K., Scherag S., Franke B., Coghill D. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur. Child. Adolesc. Psychiatry 2010, 19:237-257.
6. Banerjee E., Banerjee D., Chatterjee A., Sinha S., Nandagopal K. Selective maternal inheritance of risk alleles and genetic interaction between serotonin receptor-1B (5-HTR1B) and serotonin transporter (SLC6A4) in ADHD. Psychiatry Res. 2012, 200(2-3):1083-1085.
7. Barbarotto E., Schmittgen T.D., Calin G.A. MicroRNAs and cancer: profile, profile, profile. Int. J. Cancer 2008, 122:969-977.
8. Barbato C., Ciotti M.T., Serafino A., Calissano P., Cogoni C. Dicer expression and localization in post-mitotic neurons. Brain Res. 2007, 1175:17-27.
9. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
10. Beveridge N.J., Gardiner E., Carroll A.P., Tooney P.A., Cairns M.J. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol. Psychiatry 2010, 15:1176-1189.
11. Beveridge N.J., Tooney P.A., Carroll A.P., Gardiner E., Bowden N., Scott R.J., Tran N., Dedova I., Cairns M.J. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum. Mol. Genet. 2008, 17:1156-1168.
12. Biederman J., Faraone S.V., Keenan K., Benjamin J., Krifcher B., Moore C., Sprich-Buckminster S., Ugaglia K., Jellinek M.S., Steingard R., et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch. Gen. Psychiatry 1992, 49:728-738.
13. Biederman J., Petty C.R., Wilens T.E., Fraire M.G., Purcell C.A., Mick E., Monuteaux M.C., Faraone S.V. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am. J. Psychiatry 2008, 165:107-115.
14. Biederman J., Petty C.R., Woodworth K.Y., Lomedico A., Hyder L.L., Faraone S.V. Adult outcome of attention-deficit/hyperactivity disorder: a controlled 16-year follow-up study. J. Clin. Psychiatry 2012, 73:941-950.
15. Biederman J., Wilens T., Mick E., Milberger S., Spencer T.J., Faraone S.V. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am. J. Psychiatry 1995, 152:1652-1658.
16. Borel C., Antonarakis S.E. Functional genetic variation of human miRNAs and phenotypic consequences. Mamm. Genome 2008, 19:503-509.
17. Brunner D., Buhot M.C., Hen R., Hofer M. Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav. Neurosci. 1999, 113:587-601.
18. Buitelaar J.K. ADHD: strategies to unravel its genetic architecture. J Neural Transm Suppl. 2005, 69:1-17.
19. Carpentier P.J., Arias Vasquez A., Hoogman M., Onnink M., Kan C.C., Kooij J.J., Makkinje R., Iskandar S., Kiemeney L.A., de Jong C.A., Franke B., Buitelaar J.K. Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes. Eur. Neuropsychopharmacol. 2013, 2013 Jun;23(6):448-57.
20. Conner T.S., Jensen K.P., Tennen H., Furneaux H.M., Kranzler H.R., Covault J. Functional polymorphisms in the serotonin 1B receptor gene (HTR1B) predict self-reported anger and hostility among young men. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2010, 153B:67-78.
21. Daigre C., Roncero C., Grau-López L., Martínez-Luna N., Prat G., Valero S., Tejedor R., Ramos-Quiroga J.A., Casas M. Attention deficit hyperactivity disorder in cocaine-dependent adults: a psychiatric comorbidity analysis. Am. J. Addict. 2013, 10.1111/j.1521-0391.2012.12047.x.
22. Daigre C., Terán A., García-Vicent V., Roncero C. Attention deficit hyperactivity disorder and central nervous system depressant dependence. Adicciones 2013, 2013;25(2):171-186.
23. DeMilio L. Psychiatric syndromes in adolescent substance abusers. Am. J. Psychiatry 1989, 146:1212-1214.
24. Faraone S.V., Biederman J., Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol. Med. 2006, 36:159-165.
25. Faraone S.V., Biederman J., Wilens T.E., Adamson J. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol. Med. 2007, 37:1743-1752.
26. Faraone S.V., Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. 2010, 33:159-180.
27. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1313-1323.
28. Faraone S.V., Upadhyaya H.P. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J. Clin. Psychiatry 2007, 68:e28.
29. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K., De Girolamo G., Haro J.M., Karam E.G., Lara C., Lepine J.P., Ormel J., Posada-Villa J., Zaslavsky A.M., Jin R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry 2007, 190:402-409.
30. Feng J., Chen J., Yan J., Jones I.R., Craddock N., Cook E.H., Goldman D., Heston L.L., Sommer S.S. Structural variants in the retinoid receptor genes in patients with schizophrenia and other psychiatric diseases. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2005, 133B:50-53.
31. Fernandez-Castillo N., Roncero C., Grau-Lopez L., Barral C., Prat G., Rodriguez-Cintas L., Sanchez-Mora C., Gratacos M., Ramos-Quiroga J.A., Casas M., Ribases M., Cormand B. Association study of 37 genes related to serotonin and dopamine neurotransmission and neurotrophic factors in cocaine dependence. Genes Brain Behav. Feb 2013, 12(1):39-46. 10.1111/gbb.12013. Epub 2013 Jan 10.
32. Fiore R., Siegel G., Schratt G. MicroRNA function in neuronal development, plasticity and disease. Biochim. Biophys. Acta 2008, 1779:471-478.
33. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W., Smith B. Entrevista Clínica Estructurada para los Trastornos de la Personalidad del Eje II del DSM-IV 1999, Masson, Barcelona.
34. First MB, S.R., Gibbon M., Williams J.B.W. Entrevista clínica estructurada para los trastornos del eje I del DSM-IV 1999, Masson, Barcelona.
35. Flory K., Milich R., Lynam D.R., Leukefeld C., Clayton R. Relation between childhood disruptive behavior disorders and substance use and dependence symptoms in young adulthood: individuals with symptoms of attention-deficit/hyperactivity disorder and conduct disorder are uniquely at risk. Psychol. Addict. Behav. 2003, 17:151-158.
36. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
37. Gardiner E., Beveridge N.J., Wu J.Q., Carr V., Scott R.J., Tooney P.A., Cairns M.J. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol. Psychiatry 2012, 827-840.
38. Gonzalez J.R., Armengol L., Sole X., Guino E., Mercader J.M., Estivill X., Moreno V. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007, 23:644-645.
39. Goodman A.B. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc. Natl. Acad. Sci. USA 1998, 95:7240-7244.
40. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucl. Acids Res. 2008, 36:D154-D158.
41. Groman S.M., James A.S., Jentsch J.D. Poor response inhibition: at the nexus between substance abuse and attention deficit/hyperactivity disorder. Neurosci. Biobehav. Rev. 2009, 33:690-698.
42. Gong Y., Wu C.N., Xu J., Feng G., Xing Q.H., Fu W., Li C., He L., Zhao X.Z. Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets. Eur. Neuropsychopharmacol. 2013, 10.1016/j.euroneuro.2012.12.002.
43. Guimaraes A.P., Schmitz M., Polanczyk G.V., Zeni C., Genro J., Roman T., Rohde L.A., Hutz M.H. Further evidence for the association between attention deficit/hyperactivity disorder and the serotonin receptor 1B gene. J. Neural Transm. 2009, 116:1675-1680.
44. Hansen T., Olsen L., Lindow M., Jakobsen K.D., Ullum H., Jonsson E., Andreassen O.A., Djurovic S., Melle I., Agartz I., Hall H., Timm S., Wang A.G., Werge T. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2007, 2:e873.
45. Hawi Z., Dring M., Kirley A., Foley D., Kent L., Craddock N., Asherson P., Curran S., Gould A., Richards S., Lawson D., Pay H., Turic D., Langley K., Owen M., O'Donovan M., Thapar A., Fitzgerald M., Gill M. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol. Psychiatry 2002, 7:718-725.
46. Hollander J.A., Im H.I., Amelio A.L., Kocerha J., Bali P., Lu Q., Willoughby D., Wahlestedt C., Conkright M.D., Kenny P.J. Striatal microRNA controls cocaine intake through CREB signalling. Nature 2010, 466:197-202.
47. *, which targets the 3'-untranslated region of dynamin 1 gene (Dnm1). Int. J. Neuropsychopharmacol. 2009, 12:537-546.
48. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromol. Med. 2009, 11:173-182.
49. Huss M., Poustka F., Lehmkuhl G., Lehmkuhl U. No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study. J. Neural Transm. 2008, 115:335-339.
50. Im H.I., Hollander J.A., Bali P., Kenny P.J. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat. Neurosci. 2010, 13:1120-1127.
51. Jazdzewski K., Murray E.L., Franssila K., Jarzab B., Schoenberg D.R., de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 2008, 105:7269-7274.
52. Jensen K.P., Covault J., Conner T.S., Tennen H., Kranzler H.R., Furneaux H.M. A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Mol. Psychiatry 2009, 14:381-389.
53. Juhila J., Sipila T., Icay K., Nicorici D., Ellonen P., Kallio A., Korpelainen E., Greco D., Hovatta I. MicroRNA expression profiling reveals miRNA families regulating specific biological pathways in mouse frontal cortex and hippocampus. PLoS One 2011, 6:e21495.
54. Katusic S.K., Barbaresi W.J., Colligan R.C., Weaver A.L., Leibson C.L., Jacobsen S.J. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J. Child Adolesc. Psychopharmacol. 2005, 15:764-776.
55. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., Faraone S.V., Greenhill L.L., Howes M.J., Secnik K., Spencer T., Ustun T.B., Walters E.E., Zaslavsky A.M. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am. J. Psychiatry 2006, 163:716-723.
56. Kim A.H., Reimers M., Maher B., Williamson V., McMichael O., McClay J.L., van den Oord E.J., Riley B.P., Kendler K.S., Vladimirov V.I. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr. Res. 2010, 124:183-191.
57. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
58. Klein R.G., Mannuzza S., Olazagasti M.A., Roizen E., Hutchison J.A., Lashua E.C., Castellanos F.X. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch. Gen. Psychiatry 2012, 69(12):1295-1303.
59. Kollins S.H. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J. Atten. Disord. 2008, 12:115-125.
60. Kovacs-Nagy R., Sarkozy P., Hu J., Guttman A., Sasvari-Szekely M., Ronai Z. Haplotyping of putative microRNA-binding sites in the SNAP-25 gene. Electrophoresis 2011, 32:2013-2020.
61. Krezel W., Ghyselinck N., Samad T.A., Dupe V., Kastner P., Borrelli E., Chambon P. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998, 279:863-867.
62. Lai C.Y., Yu S.L., Hsieh M.H., Chen C.H., Chen H.Y., Wen C.C., Huang Y.H., Hsiao P.C., Hsiao C.K., Liu C.M., Yang P.C., Hwu H.G., Chen W.J. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011, 6(6):e21635.
63. Lara C., Fayyad J., de Graaf R., Kessler R.C., Aguilar-Gaxiola S., Angermeyer M., Demytteneare K., de Girolamo G., Haro J.M., Jin R., Karam E.G., Lepine J.P., Mora M.E., Ormel J., Posada-Villa J., Sampson N. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol. Psychiatry 2009, 65:46-54.
64. Levy Y., Ebstein R.P. Research review: crossing syndrome boundaries in the search for brain endophenotypes. J. Child Psychol. Psychiatry 2009, 50:657-668.
65. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
66. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
67. Li M.D., van der Vaart A.D. MicroRNAs in addiction: adaptation's middlemen?. Mol. Psychiatry 2011, 16:1159-1168.
68. Mannuzza S., Klein R.G., Bonagura N., Malloy P., Giampino T.L., Addalli K.A. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch. Gen. Psychiatry 1991, 48:77-83.
69. McGough J.J., Smalley S.L., McCracken J.T., Yang M., Del'Homme M., Lynn D.E., Loo S. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am. J. Psychiatry 2005, 162:1621-1627.
70. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 1988, 16:1215.
71. Muinos-Gimeno M., Guidi M., Kagerbauer B., Martin-Santos R., Navines R., Alonso P., Menchon J.M., Gratacos M., Estivill X., Espinosa-Parrilla Y. Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders. Hum. Mutat. 2009, 30:1062-1071.
72. Neale B.M., Medland S.E., Ripke S., Asherson P., Franke B., Lesch K.P., Faraone S.V., Nguyen T.T., Schäfer H., Holmans P., Daly M., Steinhausen H.C., Freitag C., Reif A., Renner T.J., Romanos M., Romanos J., Walitza S., Warnke A., Meyer J., Palmason H., Buitelaar J., Vasquez A.A., Lambregts-Rommelse N., Gill M., Anney R.J., Langely K., O'Donovan M., Williams N., Owen M., Thapar A., Kent L., Sergeant J., Roeyers H., Mick E., Biederman J., Doyle A., Smalley S., Loo S., Hakonarson H., Elia J., Todorov A., Miranda A., Mulas F., Ebstein R.P., Rothenberger A., Banaschewski T., Oades R.D., Sonuga-Barke E., McGough J., Nisenbaum L., Middleton F., Hu X., Nelson S. Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2010, 49:884-897. Psychiatric GWAS Consortium: ADHD Subgroup.
73. Numakawa T., Richards M., Adachi N., Kishi S., Kunugi H., Hashido K. MicroRNA function and neurotrophin BDNF. Neurochem. Int. 2011, 59:551-558.
74. Orvaschel H., Puig-Antich J., Lauderdale Fort Schedule for Affective Disorders and Schizophrenia for School-Age Children: Epidemiologic Version 1995, Nova Southeastern University, FL. (5th version ed.).
75. Pietrzykowski A.Z., Friesen R.M., Martin G.E., Puig S.I., Nowak C.L., Wynne P.M., Siegelmann H.T., Treistman S.N. Posttranscriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol. Neuron 2008, 59:274-287.
76. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
77. Prosser H.M., Koike-Yusa H., Cooper J.D., Law F.C., Bradley A. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat. Biotechnol. 2011, 29:840-845.
78. Purcell S., Cherny S.S., Sham P.C. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003, 19:149-150.
79. Quist J.F., Barr C.L., Schachar R., Roberts W., Malone M., Tannock R., Basile V.S., Beitchman J., Kennedy J.L. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Mol. Psychiatry 2003, 8:98-102.
80. Ramos-Quiroga J.A., Bosch R., Richarte V., Valero S., Gomez-Barros N., Nogueira M., Palomar G., Corrales M., Saez-Francas N., Corominas M., Real A., Vidal R., Chalita P.J., Casas M. Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. Rev. Psiquiatr. Salud Ment. 2012, 5:229-235.
81. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 2007, 8:23-36.
82. Ribases M., Hervas A., Ramos-Quiroga J.A., Bosch R., Bielsa A., Gastaminza X., Fernandez-Anguiano M., Nogueira M., Gomez-Barros N., Valero S., Gratacos M., Estivill X., Casas M., Cormand B., Bayes M. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2008, 63:935-945.
83. Ribases M., Ramos-Quiroga J.A., Hervas A., Bosch R., Bielsa A., Gastaminza X., Artigas J., Rodriguez-Ben S., Estivill X., Casas M., Cormand B., Bayes M. Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol. Psychiatry 2009, 14:71-85.
84. Rong H., Liu T.B., Yang K.J., Yang H.C., Wu D.H., Liao C.P., Hong F., Yang H.Z., Wan F., Ye X.Y., Xu D., Zhang X., Chao C.A., Shen Q.J. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J. Psychiatr. Res. 2011, 45:92-95.
85. Rosenberg N.A., Mahajan S., Ramachandran S., Zhao C., Pritchard J.K., Feldman M.W. Clines, clusters, and the effect of study design on the inference of human population structure. PLoS Genet. 2005, 1:e70.
86. Saudou F., Amara D.A., Dierich A., LeMeur M., Ramboz S., Segu L., Buhot M.C., Hen R. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 1994, 265:1875-1878.
87. Saunders M.A., Liang H., Li W.H. Human polymorphism at microRNAs and microRNA target sites. Proc. Natl. Acad. Sci. USA 2007, 104:3300-3305.
88. Saus E., Soria V., Escaramis G., Vivarelli F., Crespo J.M., Kagerbauer B., Menchon J.M., Urretavizcaya M., Gratacos M., Estivill X. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum. Mol. Genet. 2010, 19:4017-4025.
89. Schratt G.M., Tuebing F., Nigh E.A., Kane C.G., Sabatini M.E., Kiebler M., Greenberg M.E. A brain-specific microRNA regulates dendritic spine development. Nature 2006, 439:283-289.
90. Shi W., Du J., Qi Y., Liang G., Wang T., Li S., Xie S., Zeshan B., Xiao Z. Aberrant expression of serum miRNAs in schizophrenia. J. Psychiatr. Res. 2012, 46:198-204.
91. Smalheiser N.R., Lugli G., Rizavi H.S., Torvik V.I., Turecki G., Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012, 7:e33201.
92. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
93. Sun G., Yan J., Noltner K., Feng J., Li H., Sarkis D.A., Sommer S.S., Rossi J.J. SNPs in human miRNA genes affect biogenesis and function. RNA 2009, 15:1640-1651.
94. Talebizadeh Z., Butler M.G., Theodoro M.F. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res. 2008, 1:240-250.
95. Tan Z., Randall G., Fan J., Camoretti-Mercado B., Brockman-Schneider R., Pan L., Solway J., Gern J.E., Lemanske R.F., Nicolae D., Ober C. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am. J. Hum. Genet. 2007, 81:829-834.
96. van Emmerik-van Oortmerssen K., van de Glind G., van den Brink W., Smit F., Crunelle C.L., Swets M., Schoevers R.A. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012, 122:11-19.
97. Vo N., Klein M.E., Varlamova O., Keller D.M., Yamamoto T., Goodman R.H., Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. USA 2005, 102:16426-16431.
98. Wang G., van der Walt J.M., Mayhew G., Li Y.J., Zuchner S., Scott W.K., Martin E.R., Vance J.M. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 2008, 82:283-289.
99. Wilens T.E., Biederman J. Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth. J. Psychopharmacol. 2006, 20:580-588.
100. Wilens T.E., Biederman J., Kiely K., Bredin E., Spencer T.J. Pilot study of behavioral and emotional disturbances in the high-risk children of parents with opioid dependence. J. Am. Acad. Child Adolesc. Psychiatry 1995, 34:779-785.
101. Wilens T.E., Faraone S.V., Biederman J., Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111:179-185.
102. Wu J., Xiao H., Sun H., Zou L., Zhu L.Q. Role of dopamine receptors in ADHD: a systematic meta-analysis. Mol. Neurobiol. 2012, 45:605-620.
103. Wu L., Zhao Q., Zhu X., Peng M., Jia C., Wu W., Zheng J., Wu X.Z. A novel function of microRNA let-7d in regulation of galectin-3 expression in attention deficit hyperactivity disorder rat brain. Brain Pathol. 2010, 20:1042-1054.
104. Xu B., Karayiorgou M., Gogos J.A. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res. 2010, 1338:78-88.
105. Xu S., Witmer P.D., Lumayag S., Kovacs B., Valle D. MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J. Biol. Chem. 2007, 282:25053-25066.
106. Zhu Y., Kalbfleisch T., Brennan M.D., Li Y. A MicroRNA gene is hosted in an intron of a schizophrenia-susceptibility gene. Schizophr. Res. 2009, 109:86-89.